Eledon Pharmaceuticals Inc ELDN.OQ ELDN.O is expected to show no change in quarterly revenue when it reports results on November 7 (estimated) for the period ending September 30 2024
LSEG's mean analyst estimate for Eledon Pharmaceuticals Inc is for a loss of 31 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Eledon Pharmaceuticals Inc is $10.00, above its last closing price of $4.99.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2024 | -0.29 | -0.30 | -1.06 | Missed | -249.4 |
Mar. 31 2024 | -0.36 | -0.37 | -0.34 | Beat | 7 |
Dec. 31 2023 | -0.39 | -0.29 | Beat | 26 | |
Sep. 30 2023 | -0.50 | -0.46 | -0.35 | Beat | 24 |
Jun. 30 2023 | -0.46 | -0.46 | -0.40 | Beat | 12.8 |
Jan. 1 0001 | -0.58 | -0.60 | -0.75 | Missed | -25.2 |
Jan. 1 0001 | -0.78 | -0.69 | 1.6 | ||
Sep. 30 2022 | -0.68 | -0.68 | -0.73 | Missed | -7.4 |
This summary was machine generated November 6 at 13:50 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。